Easton Pharmaceuticals Announces Update to VIORRA Initiative: Manufacturing Set to Begin
February 03 2014 - 9:31AM
Marketwired
Easton Pharmaceuticals Announces Update to VIORRA Initiative:
Manufacturing Set to Begin
Company Moving Towards Meeting Its Goal of Initial Sales by the
End of First Half or Earlier, Calendar Year 2014
TORONTO, ON--(Marketwired - Feb 3, 2014) - Easton
Pharmaceuticals (OTC: EAPH) and its Consultants in Mexico, BMV
Medica S.A., announce they have advanced a timetable towards a
VIORRA product launch in Mexico, Latin America and potentially the
US, Canada and other international markets.
Easton Pharmaceuticals on account of BMV Medica and their
efforts, has an agreement in principle with a manufacturer in
Mexico, audited by the United States FDA (Food and Drug
Administration), and currently exporting a product to the United
States. This is an important material event for the company, with
VIORRA containing all GRAS ingredients (Generally Regarded As
Safe), one FDA approved manufacturer could easily supply all North
American needs, with considerably less onerous regulatory hurdles
internationally resulting in faster access to all markets.
Concurrent with the proposed manufacturing agreement, Easton is
advancing an additional tranche of funds to BMV Medica as per a
prior signed agreement between Easton and BMV.
Once final pricing and other issues have been agreed upon, a
definitive agreement will be signed and manufacturing could begin
as early as the end of February or soon afterwards, with a sales
and marketing launch in Mexico and other markets possible by May of
2014.
Ms. Mendoza Vazquez of BMV Medica stated: "We have been working
closely with Easton and the manufacturer, and have only a few
details left before signing the final agreement. This is a premium
manufacturer, with a successful audit already having been performed
by the United States FDA, ensuring a high-quality product will be
available all over North America and other parts of the world. We
expect and should have a final contract signed very soon."
Carla Pepe, current marketing director of Easton Pharmaceuticals
and lead project manager working closely with BMV, commented "We
believe the high-quality manufacturing component is an important
step in the perception of VIORRA as the intimate use by women
necessitates this level of quality. The Company is attempting to
take the proper steps to not only get to market with VIORRA as
quickly as possible but to do so in a manner that will demonstrate
the company has a high quality, safe product thanks to the diligent
work of BMV and Dr. Bagi."
As previously stated, BMV is attempting to assure Easton
Pharmaceuticals that the company shall receive not only regulatory
approval in Mexico, but also a distribution partner to coincide
with the regulatory approval. "Viorra" is an over-the-counter
aid for the treatment to restore and improve vaginal moisture and
elasticity which has a very positive effect on women's sexual
desire and arousal FSAD (Female Sexual Arousal Disorder),
VIORRA is a topical, daily-use product formulated with
ingredients classified by the FDA as Generally Recognized as
Safe.
In other developments, Easton Pharmaceuticals has executed and
closed on an agreement regarding its Medical Marijuana Initiatives.
A formal announcement is expected within a few days as well as
possible other HEMP related OTC products Easton has been
formulating.
About Easton Pharmaceuticals Easton Pharmaceuticals is a
specialty pharmaceutical company that owns, designs, develops, and
markets topically-delivered drugs and therapeutic / cosmetic
healthcare products, focused on cancer and other health issues
related towards male and female sexual dysfunction, wound healing,
pain, motion sickness, scar and stretch marks, cellulite, varicose
veins and other conditions. The company's gel formulation is
thought to be an innovative and unique transdermal delivery system.
Easton Pharmaceuticals product "VIORRA", is an
over-the-counter aid for the treatment to restore and improve
vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder) the world market for these female
conditions are conservatively estimated to be in excess of $2
billion. VIORRA is a topical, daily-use product classified
by the FDA as containing Generally Recognized as Safe
ingredients.
For More Information Visit http://www.ashleybiomedical.com
& http://www.eastonpharma.com
Safe Harbor This news release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (The "Act"). In particular, when used in the
preceding of discussion, the words "could", "pleased," "plan,"
"confident that," "believe," "expect," "possible" or "intent to"
and similar conditional expressions are intended to identify
forward-looking statements within the meaning of the Act and are
subject to the safe harbor created by the Act. Such statements are
subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, market conditions, general acceptance of
the company's products and technologies, competitive factors, the
ability to successfully complete additional or adequate financing,
government approvals or changes to proposed laws and other risks
and uncertainties further stated in the company's financial reports
and filings which all investors are advised to view.
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Apr 2023 to Apr 2024